Factors affecting the quality, safety and marketing approval of clotting factor concentrates for haemophilia

Albert Farrugia, Giancarlo M. Liumbruno, Fabio Candura, Samantha Profili, Josephine Cassar

Research output: Contribution to journalReview article

1 Citation (Scopus)

Abstract

Selecting therapeutic products for the treatment of haemophilia follows the process of obtaining market approval of products submitted to the scrutiny of a regulatory agency. In well-resourced countries, key decisions on whether a product is sufficiently safe and of high quality are made by highly expert and well-resourced agencies, such as the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA). In countries lacking such agencies, well-informed decisions can still be made through an appreciation of the key issues affecting the quality, safety and efficacy of haemophilia products. A number of well-established principles may then be applied in order to make a choice. In this review, reflecting principles outlined by the World Federation of Hemophilia, we outline the key features in determining the acceptability of therapeutic products for haemophilia in order to ensure an optimal choice in all the environments providing haemophilia care.

Original languageEnglish
Pages (from-to)525-534
Number of pages10
JournalBlood Transfusion
Volume16
Issue number6
DOIs
Publication statusPublished - Nov 1 2018

Fingerprint

Blood Coagulation Factors
Hemophilia A
Marketing
Safety
Consumer Product Safety
United States Food and Drug Administration
Therapeutics

Keywords

  • Haemophilia
  • Safety
  • Therapeutic products

ASJC Scopus subject areas

  • Immunology and Allergy
  • Hematology

Cite this

Factors affecting the quality, safety and marketing approval of clotting factor concentrates for haemophilia. / Farrugia, Albert; Liumbruno, Giancarlo M.; Candura, Fabio; Profili, Samantha; Cassar, Josephine.

In: Blood Transfusion, Vol. 16, No. 6, 01.11.2018, p. 525-534.

Research output: Contribution to journalReview article

@article{6270c425b3eb4d6d81d4c5bbdf1a342d,
title = "Factors affecting the quality, safety and marketing approval of clotting factor concentrates for haemophilia",
abstract = "Selecting therapeutic products for the treatment of haemophilia follows the process of obtaining market approval of products submitted to the scrutiny of a regulatory agency. In well-resourced countries, key decisions on whether a product is sufficiently safe and of high quality are made by highly expert and well-resourced agencies, such as the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA). In countries lacking such agencies, well-informed decisions can still be made through an appreciation of the key issues affecting the quality, safety and efficacy of haemophilia products. A number of well-established principles may then be applied in order to make a choice. In this review, reflecting principles outlined by the World Federation of Hemophilia, we outline the key features in determining the acceptability of therapeutic products for haemophilia in order to ensure an optimal choice in all the environments providing haemophilia care.",
keywords = "Haemophilia, Safety, Therapeutic products",
author = "Albert Farrugia and Liumbruno, {Giancarlo M.} and Fabio Candura and Samantha Profili and Josephine Cassar",
year = "2018",
month = "11",
day = "1",
doi = "10.2450/2018.0150-18",
language = "English",
volume = "16",
pages = "525--534",
journal = "Blood Transfusion",
issn = "1723-2007",
publisher = "Edizioni SIMTI",
number = "6",

}

TY - JOUR

T1 - Factors affecting the quality, safety and marketing approval of clotting factor concentrates for haemophilia

AU - Farrugia, Albert

AU - Liumbruno, Giancarlo M.

AU - Candura, Fabio

AU - Profili, Samantha

AU - Cassar, Josephine

PY - 2018/11/1

Y1 - 2018/11/1

N2 - Selecting therapeutic products for the treatment of haemophilia follows the process of obtaining market approval of products submitted to the scrutiny of a regulatory agency. In well-resourced countries, key decisions on whether a product is sufficiently safe and of high quality are made by highly expert and well-resourced agencies, such as the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA). In countries lacking such agencies, well-informed decisions can still be made through an appreciation of the key issues affecting the quality, safety and efficacy of haemophilia products. A number of well-established principles may then be applied in order to make a choice. In this review, reflecting principles outlined by the World Federation of Hemophilia, we outline the key features in determining the acceptability of therapeutic products for haemophilia in order to ensure an optimal choice in all the environments providing haemophilia care.

AB - Selecting therapeutic products for the treatment of haemophilia follows the process of obtaining market approval of products submitted to the scrutiny of a regulatory agency. In well-resourced countries, key decisions on whether a product is sufficiently safe and of high quality are made by highly expert and well-resourced agencies, such as the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA). In countries lacking such agencies, well-informed decisions can still be made through an appreciation of the key issues affecting the quality, safety and efficacy of haemophilia products. A number of well-established principles may then be applied in order to make a choice. In this review, reflecting principles outlined by the World Federation of Hemophilia, we outline the key features in determining the acceptability of therapeutic products for haemophilia in order to ensure an optimal choice in all the environments providing haemophilia care.

KW - Haemophilia

KW - Safety

KW - Therapeutic products

UR - http://www.scopus.com/inward/record.url?scp=85056047176&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85056047176&partnerID=8YFLogxK

U2 - 10.2450/2018.0150-18

DO - 10.2450/2018.0150-18

M3 - Review article

C2 - 30201084

AN - SCOPUS:85056047176

VL - 16

SP - 525

EP - 534

JO - Blood Transfusion

JF - Blood Transfusion

SN - 1723-2007

IS - 6

ER -